公开(公告)号：US11690888B2

公开(公告)日：2023-07-04

申请号：US16627165

申请日：2018-06-07

Applicant: DONGGUK UNIVERSITY WISE CAMPUS INDUSTRY-ACADEMY COOPERATION FOUNDATION ,  KOREA PHARMA CO., LTD.

Inventor： Dong Il Kim ,  Song Hee Jeon ,  Seung Hee Han ,  Kwang Suk Lee

IPC: A61K36/43 ,  A23L33/105 ,  A61K36/35 ,  A61K36/754

CPC classification number: A61K36/43 ,  A23L33/105 ,  A61K36/35 ,  A61K36/754 ,  A61K2236/333

Abstract: The present invention relates to a composition for preventing or treating menopausal syndrome, containing a medicinal herb extract as an active ingredient. The composition has effects of alleviating heart function deterioration and depression, which are caused by menopause, and has biostability, thereby being usable as a composition for preventing or treating female menopausal syndrome.

公开(公告)号：US11110061B2

公开(公告)日：2021-09-07

申请号：US16760995

申请日：2018-11-01

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA PHARMA CO., LTD.

Inventor： Byung Chul Shin ,  Sun Hang Cho ,  Tae Kyung Yang ,  Seok Hee Kang ,  Eun Hee Park

IPC: A61K9/16 ,  A61K31/343 ,  A61K9/00

Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.

公开(公告)号：US20240116920A1

公开(公告)日：2024-04-11

申请号：US18254927

申请日：2021-11-29

Applicant: KOREA PHARMA CO., LTD. ,  EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION

Inventor： Soo Sung KANG ,  Eun Sun PARK ,  Eun Hee PARK ,  Sun Joo LEE ,  Seung Hee HAN

IPC: C07D471/04 ,  A61P1/16

CPC classification number: C07D471/04 ,  A61P1/16

Abstract: Provided is a novel JAK-specific inhibitor compound and a method for preparing the same. The compound of the provided can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases. In particular, due to its high selectivity for JAK1, the compound of the provided can exhibit better therapeutic effects on inflammatory diseases and autoimmune diseases at a low dose and with fewer side effects and can be expected to be effective in preventing and treating liver fibrosis.

公开(公告)号：US20220220109A1

公开(公告)日：2022-07-14

申请号：US17613291

申请日：2020-05-27

Applicant: KOREA PHARMA CO., LTD.

Inventor： Soosung KANG ,  Eun Sun PARK ,  Eun Hee PARK ,  Seung Hee HAN

IPC: C07D471/04

Abstract: The present invention relates to a JAK inhibitor compound and a pharmaceutical composition including the same. More specifically, the present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutical composition including the same. The structure of the compound of Formula I is described in the specification. The compound of the present invention can exhibit therapeutic effects on a variety of diseases, for example, inflammatory diseases, autoimmune diseases, myeloproliferative diseases, and human cancers due to its ability to regulate signal transduction at the level of JAK kinases.

公开(公告)号：US20200281856A1

公开(公告)日：2020-09-10

申请号：US16760995

申请日：2018-11-01

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KOREA PHARMA CO., LTD.

Inventor： Byung Chul SHIN ,  Sun Hang CHO ,  Tae Kyung YANG ,  Seok Hee KANG ,  Eun Hee PARK

IPC: A61K9/16 ,  A61K31/343

Abstract: The present invention relates to a biodegradable polymer microsphere-containing sustained-release injection containing escitalopram as an active ingredient, and to a method for manufacturing the same. In the case of escitalopram microspheres, there is a problem of low encapsulation rate, fracture due to weak strength, and initial over-release due to the phase separation of the liquid drug and the polymer inside the microspheres. In order to solve the problem, it is possible to maximize the encapsulation amount and the encapsulation efficiency of the escitalopram adding a hydrophobic solidifying agent to uniformize the non-uniform phase, to overcome the cracking of the microspheres at high loading conditions, and to properly control the initial release and release delay of the microspheres.